I-Mab (NASDAQ:BDTX) announced its earnings results on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.03, Fidelity Earnings reports.

I-Mab stock opened at $29.87 on Friday. The firm has a market cap of $1.18 billion and a PE ratio of -1.76. I-Mab has a 1-year low of $17.63 and a 1-year high of $46.25. The stock has a fifty day simple moving average of $33.71.

In related news, major shareholder Versant Venture Capital Vi, L. sold 5,492 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $33.04, for a total value of $181,455.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bradley J. Phd Bolzon sold 6,217 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $33.04, for a total value of $205,409.68. Following the completion of the transaction, the director now owns 1,491 shares of the company’s stock, valued at approximately $49,262.64. The disclosure for this sale can be found here.

Several analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $53.00 target price on shares of I-Mab in a research report on Wednesday. Canaccord Genuity reaffirmed a “buy” rating and set a $50.00 target price on shares of I-Mab in a research report on Thursday, May 21st. Finally, Zacks Investment Research raised I-Mab from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Wednesday. Six analysts have rated the stock with a buy rating, I-Mab currently has an average rating of “Buy” and an average target price of $45.60.

I-Mab Company Profile

Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

Read More: What is the Current Ratio?

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.